Spots Global Cancer Trial Database for Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Official Title: Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream
Study ID: NCT04842422
Conditions
Interventions
Study Description
Brief Summary: Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.
Detailed Description:
Keywords
Eligibility
Minimum Age: 50 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Locations
Universitätsklinik für Dermatologie und Venerologie, Graz, , Austria
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
